The coming winter may bring a simplified approach to respiratory illness prevention. For the first time, Europeans could soon have access to a single vaccine offering protection against both influenza and COVID-19. The development, spearheaded by Moderna, addresses a common hesitancy among individuals like Élisabeth, who, according to reports, prefers to receive the influenza and COVID-19 vaccines at separate appointments due to concerns about potential side effects. As reported by Le Parisien, this preference highlights a broader public desire for a more convenient and potentially less burdensome vaccination experience.
The combined vaccine, known as mCombriax, has received a positive opinion from the European Medicines Agency (EMA), paving the way for potential market authorization. According to the EMA, mCombriax is designed for individuals aged 50 and older, offering a single shot to protect against both viruses. This innovation leverages messenger RNA (mRNA) technology, the same platform used in some of the highly effective COVID-19 vaccines developed during the pandemic. The COVID-19 component of the vaccine targets a SARS-CoV-2 strain based on the EMA’s recommendation for the 2023/2024 season, while the influenza strains align with the World Health Organization’s (WHO) recommendations for the same period.
Addressing Low Vaccination Rates with a Combined Approach
The development of a combined vaccine comes at a time when vaccination rates for both influenza and COVID-19 remain below optimal levels in many European countries. Data from the 2025-2026 vaccination campaign, which concluded on February 28th, 2026, reveals that despite recommendations from the French Ministry of Health to administer both vaccines simultaneously, coverage rates among individuals over 65 years of age were only 53% for influenza and a significantly lower 15% for COVID-19. Le Parisien reported these figures, highlighting a clear need for strategies to improve vaccine uptake.
Public health officials hope that the convenience of a single, combined vaccine will encourage more people to get vaccinated, particularly those who are hesitant to receive multiple injections. The logistical challenges of scheduling and attending separate appointments, coupled with concerns about potential side effects, can be significant barriers to vaccination. A combined vaccine aims to address these barriers, making protection against both influenza and COVID-19 more accessible and appealing.
mRNA Technology: A Key Enabler of Vaccine Innovation
The success of mRNA technology in the development of COVID-19 vaccines has spurred significant investment and research into its potential applications beyond COVID-19. MRNA vaccines work by delivering genetic instructions to the body’s cells, prompting them to produce a harmless piece of the virus. This triggers an immune response, preparing the body to fight off the actual virus if exposed. The flexibility of the mRNA platform allows for rapid adaptation to novel viral strains, making it an ideal technology for developing vaccines against rapidly evolving viruses like influenza and SARS-CoV-2.
Moderna’s mCombriax vaccine represents a significant step forward in vaccine technology, demonstrating the potential of mRNA to address multiple infectious diseases simultaneously. This approach could streamline vaccination campaigns, reduce healthcare costs and ultimately improve public health outcomes. The EMA’s positive opinion is based on a rigorous review of clinical trial data, confirming the vaccine’s safety and efficacy.
Impact on Vaccination Campaigns and Public Health
The introduction of a combined influenza and COVID-19 vaccine is expected to have a significant impact on upcoming vaccination campaigns. Health authorities will need to adjust their strategies to incorporate the new vaccine, ensuring that it is readily available to those who are eligible. The target population for mCombriax is currently defined as individuals 50 years and older, but future recommendations may expand to include other age groups or risk categories.
The potential benefits of increased vaccination rates extend beyond individual protection. Higher levels of population immunity can facilitate to reduce the spread of both influenza and COVID-19, protecting vulnerable individuals and lessening the burden on healthcare systems. Here’s particularly important as we continue to navigate the ongoing evolution of these viruses and the potential for new variants to emerge. The European Centre for Disease Prevention and Control (ECDC) will likely play a key role in monitoring the impact of the combined vaccine on disease transmission and severity.
Challenges and Considerations
While the development of a combined vaccine is a promising development, several challenges and considerations remain. One potential concern is the possibility of immune interference, where the immune response to one virus may affect the response to the other. However, clinical trial data suggests that mCombriax elicits robust immune responses to both influenza and COVID-19, without significant interference.
Another consideration is the need to update the vaccine composition annually to account for changes in circulating viral strains. Both influenza and SARS-CoV-2 are prone to mutation, requiring ongoing surveillance and adaptation of vaccine formulations. The EMA and WHO will continue to monitor viral evolution and provide recommendations for vaccine updates as needed. Ensuring equitable access to the vaccine across all European countries will be crucial to maximizing its public health impact.
Looking Ahead: The Future of Combination Vaccines
The success of mCombriax could pave the way for the development of combination vaccines targeting other infectious diseases. Researchers are exploring the possibility of combining vaccines against multiple respiratory viruses, such as influenza, COVID-19, and respiratory syncytial virus (RSV). Such vaccines could offer even greater convenience and protection, simplifying vaccination schedules and reducing the overall burden of respiratory illness.
The ongoing investment in mRNA technology and vaccine research is driving innovation in the field of infectious disease prevention. The development of mCombriax is a testament to the power of scientific collaboration and the potential of new technologies to address global health challenges. As we move forward, continued vigilance, research, and investment will be essential to protect against emerging infectious threats and improve the health and well-being of populations worldwide.
The EMA is expected to create a final decision on the authorization of mCombriax in the coming weeks. Once authorized, the vaccine will be available to European Union member states for inclusion in their national vaccination programs. Individuals are encouraged to consult with their healthcare providers to determine if the combined vaccine is appropriate for them. Stay informed about the latest updates on vaccine availability and recommendations from your local health authorities.
Key Takeaways:
- Moderna’s mCombriax is a first-of-its-kind vaccine protecting against both influenza and COVID-19.
- The vaccine has received a positive opinion from the European Medicines Agency (EMA) for use in individuals 50 years and older.
- The combined vaccine aims to improve vaccination rates by offering a more convenient and accessible option.
- mRNA technology plays a crucial role in the rapid development and adaptation of this vaccine.
This is a developing story. We will continue to provide updates as more information becomes available.
Related reading